Abstract
Limited data exist regarding the incidence and factors associated with outcome of invasive Pseudomonal infections in hematopoietic cell transplant (HCT). A retrospective analysis of cases of invasive Pseudomonas aeruginosa infection and factors associated with outcome was performed. P. aeruginosa invasive infection occurred in 95 of 5772 patients (1.65%) a median of 63 days after HCT (range 5–1435). Only 28% of infections occurred during periods of neutropenia (absolute neutrophil count<500 cells/mm3). Infection-attributable mortality during the initial episode of infection was 35.8%. Factors associated with initial mortality included the presence of a copathogen and high-dose steroid use. Ten (16.4%) of those who survived the initial infection experienced a recurrence of P. aeruginosa infection at a median of 9 days (range 3–17) after stopping antibiotics and 60% of those died as a result of recurrent infection a median of 1 day (range 1–7) after onset of recurrence. Grade 3–4 graft-versus-host disease was associated with a higher risk of recurrent infection. The risk of recurrence was not influenced by the presence of copathogens. Thus, invasive P. aeruginosa infections are associated with high recurrence rates and mortality in this immunocompromised population. Aggressive attempts to reduce immunosuppression and to treat copathogens may help during the initial infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nichols WG, Corey L, Gooley T, Davis C, Boeckh M . High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273–282.
Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.
Williamson EC, Millar MR, Steward CG, Cornish JM, Foot AB, Oakhill A et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560–568.
Lossos IS, Breuer R, Or R, Strauss N, Elishoov H, Naparstek E et al. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study. Transplantation 1995; 60: 672–678.
Walter EA, Bowden RA . Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995; 9: 823–847.
Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998; 21: 1137–1143.
Sayer HG, Longton G, Bowden R, Pepe M, Storb R . Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328–1332.
Parkkali T, Ruutu T, Stenvik M, Kuronen T, Kayhty H, Hovi T et al. Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. Apmis 1996; 104: 383–388.
Bodey GP, Buckley M, Sathe YS, Freireich EJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340.
Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH . Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77: 707–714.
Anonymous. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 1994; 272: 1183–1189.
Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106: 1–7.
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239–250.
Petersen F, Thornquist M, Buckner C, Counts G, Nelson N, Meyers J et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16: 199–208.
Collin BA, Leather HL, Wingard JR, Ramphal R . Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947–953.
Pollack M . Pseudomonas aeruginosa and related bacteria. In: Blacklow NR (ed). Infectious Diseases, 2nd edn. WB Saunders: New York, 1998.
Wendt C, Messer SA, Hollis RJ, Pfaller MA, Wenzel RP, Herwaldt LA . Recurrent gram-negative bacteremia: incidence and clinical patterns. Clin Infect Dis 1999; 28: 611–617.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751.
Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Levine AS, Deisseroth AB et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194–200.
Pfaller MA, Hollis RJ, Sader HS . PFGE of chromosomal restriction fragments. In: Isenberg HD (ed). Clinical Microbiology Procedures Handbook, Suppl 1. American Society for Microbiology: Washington DC, 1992, pp 10.5.c.1–10.5.c.11.
Wendt C, Messer SA, Hollis RJ, Pfaller MA, Wenzel RP, Herwaldt LA . Molecular epidemiology of gram-negative bacteremia. Clin Infect Dis 1999; 28: 605–610.
Mitchell AE, Derrington P, Turner P, Hunt LP, Oakhill A, Marks DI . Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004; 33: 303–310.
Capdevila JA, Almirante B, Pahissa A, Planes AM, Ribera E, Martinez-Vazquez JM . Incidence and risk factors of recurrent episodes of bacteremia in adults. Arch Intern Med 1994; 154: 411–415.
Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512–520.
Acknowledgements
This study was supported NIH 18029 (MB), NIH 15704 (MB), The Joel Meyers Endowment Fund of the FHCRC (MH). We thank Rachel A Carter and Gary Schoch of the FHCRC for assistance with statistical analyses and database services, Bruce Ulness of the University of Washington microbiology laboratory for bacterial sensitivities, and the Department of Laboratory Medicine at the University of Washington for performing the PFGE analyses.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hakki, M., Limaye, A., Kim, H. et al. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant 39, 687–693 (2007). https://doi.org/10.1038/sj.bmt.1705653
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705653